{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spiriva+Handihaler%C2%AE", "query": { "intervention": "Spiriva Handihaler®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spiriva+Handihaler%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T20:17:18.823Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01696058", "title": "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Tiotropium", "type": "DRUG" }, { "name": "Placebo matching Olodaterol", "type": "DRUG" }, { "name": "Olodaterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1137, "start_date": "2012-09", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-11-25", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 94, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01696058" }, { "nct_id": "NCT03095456", "title": "Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease, COPD", "Low Peak Inspiratory Flow Rate (PIFR)" ], "interventions": [ { "name": "Revefenacin", "type": "DRUG" }, { "name": "Spiriva Handihaler®", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo for Revefenacin", "type": "DRUG" }, { "name": "Placebo for Spiriva Handihaler®", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Mylan Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 207, "start_date": "2017-03-27", "completion_date": "2017-11-25", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 1, "location_summary": "Rock Hill, South Carolina", "locations": [ { "city": "Rock Hill", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095456" }, { "nct_id": "NCT01426009", "title": "Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "EP-101 via nebulizer (eFlow®) 25 ug", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 50 ug", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 100 ug", "type": "DRUG" }, { "name": "Placebo EP-101", "type": "DRUG" }, { "name": "Tiotropium bromide via (Spiriva® Handihaler®)", "type": "DRUG" }, { "name": "Ipratropium bromide Inhalation Solution via Handihaler® DPI", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 200 ug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunovion Respiratory Development Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 140, "start_date": "2011-08", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "North Dartmouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01426009" }, { "nct_id": "NCT01854645", "title": "Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "GFF MDI", "type": "DRUG" }, { "name": "GP MDI", "type": "DRUG" }, { "name": "FF MDI", "type": "DRUG" }, { "name": "Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)", "type": "DRUG" }, { "name": "Placebo MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 2103, "start_date": "2013-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 121, "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854645" }, { "nct_id": "NCT00929110", "title": "1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Glycopyrronium bromide", "type": "DRUG" }, { "name": "Placebo to glycopyrronium bromide", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1066, "start_date": "2009-06", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-08-17", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00929110" }, { "nct_id": "NCT05165485", "title": "Phase 4 COPD and Suboptimal Inspiratory Flow Rate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Revefenacin", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" }, { "name": "Revefenacin Placebo", "type": "DRUG" }, { "name": "Tiotropium Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 404, "start_date": "2022-01-07", "completion_date": "2023-11-20", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 76, "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05165485" }, { "nct_id": "NCT00668772", "title": "Tiotropium/Salmeterol Inhalation Powder in COPD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Tiotropium/Salmeterol", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 207, "start_date": "2008-04-15", "completion_date": "2008-11-21", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 16, "location_summary": "Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668772" }, { "nct_id": "NCT01587079", "title": "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "PT003", "type": "DRUG" }, { "name": "PT001", "type": "DRUG" }, { "name": "PT005", "type": "DRUG" }, { "name": "Tiotropium inhalation powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 159, "start_date": "2012-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 19, "location_summary": "Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01587079" }, { "nct_id": "NCT00900731", "title": "A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Indacaterol 150 μg", "type": "DRUG" }, { "name": "Tiotropium 18 μg", "type": "DRUG" }, { "name": "Placebo to indacaterol", "type": "DRUG" }, { "name": "Placebo to tiotropium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1598, "start_date": "2009-06", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-08-19", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900731" }, { "nct_id": "NCT01483625", "title": "Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "tiotropium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 140, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-26T20:17:18.823Z", "location_count": 27, "location_summary": "Tucson, Arizona • Riverside, California • San Diego, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483625" } ] }